June 7th 2025
The findings are notable in part because therapies have already been approved to target C5aR1 in other diseases.
New Drug Approvals in Leukemia and Lymphoma Presented at ASH 2017
Average Profit Margin on Oncology Drugs for 340B Hospitals Nears 50%
Report Highlights Increase in Premature Deaths in the United States
FDA Announces Public Education Campaign to Encourage Smoking Cessation